Home/Filings/3/A/0001209191-20-005857
3/A//SEC Filing

Frazier Life Sciences VIII, L.P. 3/A

Accession 0001209191-20-005857

CIK 0001787306other

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 6:29 PM ET

Size

12.9 KB

Accession

0001209191-20-005857

Insider Transaction Report

Form 3/AAmended
Period: 2020-01-30
Holdings
  • Common Stock

    509,032
  • Series C Preferred Stock

    Exercise: $0.00Common Stock (1,074,467 underlying)
  • Series A Preferred Stock

    Exercise: $0.00Common Stock (6,360,272 underlying)
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (2,099,019 underlying)
Holdings
  • Series A Preferred Stock

    Exercise: $0.00Common Stock (6,360,272 underlying)
  • Series C Preferred Stock

    Exercise: $0.00Common Stock (1,074,467 underlying)
  • Common Stock

    509,032
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (2,099,019 underlying)
Holdings
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (2,099,019 underlying)
  • Series C Preferred Stock

    Exercise: $0.00Common Stock (1,074,467 underlying)
  • Series A Preferred Stock

    Exercise: $0.00Common Stock (6,360,272 underlying)
  • Common Stock

    509,032
Holdings
  • Common Stock

    509,032
  • Series A Preferred Stock

    Exercise: $0.00Common Stock (6,360,272 underlying)
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (2,099,019 underlying)
  • Series C Preferred Stock

    Exercise: $0.00Common Stock (1,074,467 underlying)
Footnotes (2)
  • [F1]The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.
  • [F2]Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

Issuer

Arcutis Biotherapeutics, Inc.

CIK 0001787306

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001655827

Filing Metadata

Form type
3/A
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 6:29 PM ET
Size
12.9 KB